- Innovation Pharmaceuticals (OTCQB:IPIX -1.3%) announces that enrollment in the company’s 120-patient, Phase 2 clinical trial of Brilacidin for COVID-19 has reached 90 percent.
- The company said that it anticipates full enrollment to be completed in about two weeks.
- Innovation is developing Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients under U.S. FDA Fast Track designation.
- The company had announced that eight sites were participating in the mid-stage Brilacidin COVID-19 trial, in March.
Patient enrollment reaches 90 percent in Innovation Pharmaceuticals' mid-stage COVID-19 trial
Recommended For You
About IPIX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
IPIX | - | - |
Innovation Pharmaceuticals Inc. |